THE US Food and Drug
Administration has approved
Cometriq (cabozantinib) to treat
medullary thyroid cancer that has
spread to other parts of the body
(metastasised).
Cometriq is a kinase inhibitor that
blocks abnormal kinase proteins
involved in the development and
growth of medullary cancer cells.
Patients should not eat for at
least 2 hours before and 1 hour
after taking Cometriq.
See www.fda.gov.The above article was sent to subscribers in Pharmacy Daily's issue from 04 Dec 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Dec 12
THE Australian Commission on Safety and Quality in Health Care has today launched a national Standard to improve the care of people with cognitive disabilities or impairments.
AUSTRALIAN mothers and their babies experienced some positive outcomes during the early years of the pandemic, new research from the Australian Institute of Health and Welfare (AIHW) has discovered.
AUSTRALIA needs more pharmacists than ever, in the face of an ageing population and rising healthcare demands, according to the Pharmaceutical Society of Australia (PSA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.